Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL1102 in non-ambulatory Duchenne muscular dystrophy
ACTRN12618000970246Phase 2Completed
- Sponsor
- Percheron Therapeutics Ltd
- Start
- Aug 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avicursen in Duchenne muscular dystrophy (DMD), sponsored by Percheron Therapeutics Ltd. Primary endpoint: Safety and tolerability. Started Aug 2018; status: completed.
02
Drugs
avicursen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on ACTRN12618000970246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000970246.